

**“How Do Patents Affect Follow-On Innovation? Evidence from the Human Genome”**  
**AER Manuscript #20151398**

**Disclosure statement by Bhaven Sampat**

(1) As detailed in the opening footnote, this paper received financial support from several sources:

- The National Institute on Aging (NIA) and the NIH Common Fund, Office of the NIH Director, through Grants T32-AG000186 and U01-AG046708 to the National Bureau of Economic Research (NBER)
- The Ewing Marion Kauffman Foundation
- The NBER Innovation Policy and the Economy program
- NSF Grant Number 1151497
- Toulouse Network for Information Technology

(2) In addition to the sources listed above, over the past three years I have received more than \$10,000 in research funding from the UK Economic and Social Research Council (Grant Number ES/K010999/1) and the National Science Foundation (Grant Numbers 1732544 and 1735413) and the National Bureau of Economic Research Value of Health Research Network (sponsored by the National Institute on Aging)

(3) I do not have any paid or unpaid positions as officer, director, or board member of a relevant non-profit organization or profit-making entity.

(4) My spouse is an unpaid board member at the Initiative for Medicines, Access, and Knowledge (I-MAK) a non-profit organization which does work on drug patents (but, to my knowledge, not on gene patents).

(5) No party had the right to review the submitted paper.

Two data sets used in this paper --- the Pharmaprojects data, collected by a private company (Citeline; <https://citeline.com/contact/contact-us/>); and the Thomson Innovation data, also collected by a private company (<https://clarivate.com/products/derwent-innovation/>) --- are proprietary and cannot be posted online, but are available for purchase.